ChemoCentryx (CCXI) Files $57.5M IPO
Up)
ChemoCentryx (Nasdaq: CCXI) filed a registration statement with the SEC for an initial public offering of its common stock. The proposed maximum aggregate offering price is $57.5 million. The company plans to list on the NASDAQ under the stock symbol "CCXI."
The offering is being made through Credit Suisse, Cowen and Company, Leerink Swann and Lazard Capital Markets.
ChemoCentryx is focused exclusively on the discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The chemokine system is a complex network of molecules that regulates cell migration and directs and coordinates the inflammatory immune response.
The offering is being made through Credit Suisse, Cowen and Company, Leerink Swann and Lazard Capital Markets.
ChemoCentryx is focused exclusively on the discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The chemokine system is a complex network of molecules that regulates cell migration and directs and coordinates the inflammatory immune response.
You May Also Be Interested In
- ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant Association Congress
- UBS Maintains a 'Neutral' on Equity Residential (EQR); Lehman Walks Away With Archstone Stake; IPO Could Be On The Way
- Intelsat Global Holdings SA (I) Files $1.75B IPO
Create E-mail Alert Related Categories
IPOsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
